Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help ...

Steve Dorsey has issued a stark warning for his fellow firefighters to check on one common undetected cancer symptom.

Firefighters have a 62% higher likelihood of getting esophageal cancer because of the occupational risk from exposure to ...

Esophageal cancer is an aggressive, deadly cancer often caught in advanced stages. The likelihood of surviving for five years ...

PAVmed (NASDAQ:PAVM) is scheduled to announce Q1 earnings results on Thursday, May 15th, before market open. The consensus EPS Estimate is -$0.29 (+70.7% Y/Y) and the consensus Revenue Estimate is $0.

PAVmed (NASDAQ:PAVM) and its subsidiary Lucid Diagnostics (NASDAQ:LUCD) on Thursday reported data from a study showing that its EsoGuard esophageal DNA test can detect esophageal precancer in at ...

Lucid Diagnostics (LUCD) shared new data from a National Cancer Institute (NCI)-sponsored study that supports the broader utility of its EsoGuard(R) Esophageal DNA Test. The study, conducted in ...

Lucid's EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device, represent the first and ...

Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing For more information about Lucid, please visit www.luciddx.com and for more information about ...

Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing This press release includes forward-looking statements that involve risk and uncertainties.